TULIP: trastuzumab duocarmazine improved PFS in pre-treated HER2+ breast cancer

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metas...Подробнее

Trastuzumab Duocarmazine for HER2+ Locally Advanced or Metastatic CancerПодробнее

Treatment Updated for HER2 Positive Breast Cancer: Changing ParadigmsПодробнее

Study of Immunotherapy Combinations for Patients with HER2-Positive Metastatic Breast CancerПодробнее

HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic...Подробнее

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment ApproachesПодробнее

Breast cancer trial updates at ESMO 2021Подробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. GradisharПодробнее

Adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in HER2-positive breast cancerПодробнее

Study of Targeted Therapy for HER2-Positive Metastatic Breast CancerПодробнее

HER2CLIMB-05: tucatinib + trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic BCПодробнее

FAQ series: How is secondary breast cancer treated? HER2 receptiveПодробнее

Dr. Pegram on Pertuzumab Plus Trastuzumab and Chemotherapy in Breast CancerПодробнее

Study comparing margetuximab combinations to trastuzumab combinations in HER2-positive breast cancerПодробнее

Poziotinib for HER2-positive metastatic breast cancerПодробнее

Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast CancerПодробнее

Study of Atezolizumab with Pertuzumab and Trastuzumab in HER2- Positive Metastatic Breast CancerПодробнее

Effect of Trastuzumab-based Therapy on Survival in Small, Node-Negative HER2-positive Breast CancerПодробнее

Dr. Hurvitz on Eliminating Anthracyclines in HER2+ Breast Cancer TreatmentПодробнее